4.3 Guideline Recommendations on LMCAD Revascularization -- 4.4 Individualized Patient Approach -- 4.4.1 Predicted Surgical Risk -- 4.4.2 Anatomy of CAD -- 4.4.3 Completeness of Revascularization -- 4.4.4 Procedural Urgency -- 4.4.5 Clinical Characteristics -- 4.4.5.1 Diabetes Mellitus -- 4.4.5.2 Heart Failure with Reduced Ejection Fraction -- 4.4.5.3 Chronic Kidney Disease -- 4.4.5.4 Bleeding Risk -- 4.4.5.5 General Status of the Patient -- 4.5 Conclusions -- References -- 5: CABG Should Be the First Option for Left Main Disease: A Cardiac Surgeon's Perspective -- 5.1 Introduction -- 5.2 When PCI Is the Better Choice? -- 5.3 When Surgery Is the Better Choice? -- 5.4 Conclusions -- References -- 6: PCI Should Be the First Option for All Left Main Disease? An Interventional Cardiologist's Perspective -- 6.1 Introduction -- 6.2 Not all LMS Disease is the Same -- 6.3 The Evidence -- 6.4 Longer Term Outcomes PCI vs CABG -- 6.5 Limitations of Trials to Date -- 6.6 PCI Technique and Strategy -- 6.7 PCI in the Emergency Setting -- 6.8 Unanswered Questions -- 6.9 Conclusion -- References -- 7: Which Interventional Device for Left Main PCI? A Description of Available Stents -- 7.1 Introduction -- 7.1.1 Xience (Abbott Vascular, Santa Clara, CA, USA) -- 7.1.2 Xience Vs Synergy -- 7.1.3 Biomatrix ™ Stent -- 7.1.4 Resolute Onyx -- 7.1.5 Orsiro Sirolimus-Eluting Stent -- 7.1.6 Ultimaster™ Tansei™ Stent (Terumo Corporation, Tokyo, Japan) -- 7.1.7 Xposition S Sirolimus-Eluting Stent (Stentys, Paris, France) -- 7.1.8 Dedicated Bifurcation Stent -- 7.2 Conclusion -- References -- 8: Which Interventional Technique for Left Main PCI? -- 8.1 Introduction -- 8.2 What Is Special About the Left Main Stem? -- 8.3 Provisional Side Branch Stenting -- 8.4 Systematic Two-Stent Approach -- 8.5 Difficult Wire Access. |